Expression of miR-101-3p and its target ADAM15 gene in colorectal cancer patients
Abstract
Purpose: This study aims to evaluate the expression patterns of miR-101-3p and its target ADAM15 in colorectal cancer patients. Materials and Methods: Thirty patients with colorectal cancer had their tumor and corresponding normal tissue samples taken. Following RNA extraction, real-time PCR (qRT-PCR) was used to determine the relative expression of miR-101-3p and its anticipated target gene, ADAM15, using β-actin as a housekeeping gene. The 2^–ΔΔCt technique was used to determine the relative gene expression levels Results: Considering colorectal malignant tissues compared to their surrounding non-cancerous counterparts, miR-101-3p expression was significantly lower. On the other hand, tumor tissues showed noticeably higher levels of ADAM15 mRNA. The expression levels of miR-101-3p and ADAM15 were shown to be significantly inversely correlated (r = -0.6719, p < 0.05). Conclusion: Our results suggest that miR-101-3p potentially regulates the expression of ADAM15, whose upregulation is associated with tumor tissues. The hypothesis that their interaction may play a significant role in the pathogenesis of CRC is supported by the inverse correlation between these two markers. More studies are required, particularly with bigger patient populations. These results highlight the potential of the miR-101-3p/ADAM15 pathway as a useful biomarker for the future diagnosis or treatment of colorectal cancer.
Keywords
MicroRNA-101-3p , Adam 15 , colorectal cancer , gene expression
Kaynakça
- Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44:222-36.
- Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338-44.
- Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements. Int J Mol Sci. 2020;22:130.
- Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7:335-46.
- Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench. 2013;6:120-8.
- Yi R, Li Y, Wang FL, Miao G, Qi RM, Zhao YY. MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol. 2016;8:330-40.
- Ziemann M, Lim SC, Kang Y, Samuel S, Sanchez IL, Gantier M et al. MicroRNA-101-3p modulates mitochondrial metabolism via the regulation of complex II assembly. J Mol Biol. 2022;434:167361.
- Farc O, Budisan L, Zaharie F, Țăulean R, Vălean D, Talvan E et al. Expression and functional analysis of immuno-microRNAs miR-146a and miR-326 in colorectal cancer. Curr Issues Mol Biol. 2024;46:7065-85.
- Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008;68:6416-24.
- Fujiwara Y, Saito M, Robles AI, Nishida M, Takeshita F, Watanabe M, et al. A nucleolar stress-specific p53-miR-101 molecular circuit functions as an intrinsic tumor-suppressor network. EBioMedicine. 2018;33:33-48.
